Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.16548 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing the efficacy of oral apremilast, intralesional corticosteroids, and their combination in patients with patchy alopecia areata: a randomized clinical controlled trial.
Arch Dermatol Res
December 2024
Department of Dermatology, Venereology and Leprology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India.
Introduction: Alopecia areata (AA) is a chronic, immune-mediated inflammatory disorder characterized by nonscarring hair loss. The management of AA poses challenges due to its unpredictable course and variable response to treatment. In this comparative study, we evaluated the efficacy and safety of oral apremilast, intralesional corticosteroids (ILC) and a combination of both in patients with patchy AA.
View Article and Find Full Text PDFA systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease.
Australas J Dermatol
December 2024
Department of Dermatology, Skin Health Institute, Melbourne, Victoria, Australia.
This study systematically reviews existing data on the efficacy of Tyrosine Kinase 2 (TYK2) inhibitors in comparison to placebo or standard treatments for therapeutic benefit and improving quality of life in dermatological diseases. Seventeen records representing 13 clinical trials, one matching-adjusted indirect comparison, and one case study were included. Results indicate that Deucravacitinib is superior to placebo, Apremilast and Adalimumab in treating adult patients with moderate-to-severe plaque psoriasis and superior to placebo in the treatment of adults with systemic lupus erythematosus.
View Article and Find Full Text PDFSelective small molecule inhibitors for hidradenitis suppurativa: Today and tomorrow.
J Am Acad Dermatol
December 2024
Department of Dermatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, University of Minnesota, Minneapolis, Minnesota; Departments of Medicine and Dermatology, Minneapolis VA Health Care System, Minneapolis, Minnesota. Electronic address:
Hidradenitis suppurativa (HS) is an autoinflammatory condition characterized by abscesses, inflammatory nodules, and tunnels in intertriginous sites of the body. The pathogenesis of HS involves follicular occlusion in combination with environmental, genetic, hormonal, and metabolic factors. HS lesions are characterized by an influx of neutrophils, histiocytes, B and T cells, and upregulation of proinflammatory cytokines such as tumor necrosis factor-α, interleukin-1, interleukin-17, and interferons.
View Article and Find Full Text PDFSafety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.
JAMA Dermatol
November 2024
Oregon Medical Research Center, Portland, Oregon.
Importance: Safe and effective long-term treatments for moderate to severe plaque psoriasis are needed.
Objective: To evaluate the long-term safety and efficacy of deucravacitinib through 3 years (week 148) in the randomized POETYK PSO-1, PSO-2, and nonrandomized long-term extension (LTE) trials.
Design, Setting, And Participants: PSO-1/PSO-2 were global, 52-week, randomized, double-blinded phase 3 trials in patients with moderate to severe plaque psoriasis.
EFFECTIVENESS AND TOLERABILITY OF APREMILAST IN TREATMENT OF A SAMPLE OF PATIENTS WITH PSORIASIS.
Georgian Med News
September 2024
2Department of Pharmacology, College of Medicine, University of Baghdad, Iraq.
Aim: Current study was aimed to appraise the effectiveness and tolerability of apremilast in psoriasis patients at AL-Diwaniyah province, Iraq.
Materials And Methods: This prospective cross-sectional study conducted at Dermatology Unit/ AL-Diwaniyah Teaching Hospital/ Iraq, during the period from January to October 2023. A total of 125 patients, 90 males and 35 females, were enrolled in this study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!